NFKB1 and cancer: Currently, numerous cancer-selective agents targeting upstream activators or downstream effectors of the NF-κB pathway that are able to circumvent the adverse effects associated with the systemic targeting of NF-κB, are being tested in clinical studies [40,41,211,212,213,214,215].